secwatch.observer — SEC 8-K summary
======================================

Issuer:     Transcode Therapeutics, Inc. (RNAZ)
CIK:        0001829635
Form:       8-K
Filed at:   2026-02-23T23:59:59+00:00
Accession:  0001104659-26-018362
Event type: other_material
Sentiment:  neutral
Materiality: 0.30
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

TransCode publishes preclinical RIG-I agonist data in Molecular Imaging and Biology
--------------------------------------------------------------------------------

- Manuscript published Feb 19, 2026 in Molecular Imaging and Biology.
- Novel template-driven RIG-I agonist activates innate immunity selectively in tumor cells.
- Uses overexpressed miRNA-21 as intracellular assembly template; aims to reduce systemic toxicity.
- Study conducted with Prof. Anna Moore (Michigan State Univ.) and TransCode CSO Zdravka Medarova.
- TTX nanoparticle delivery platform underpins the approach; currently in clinical trials.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1829635/000110465926018362/0001104659-26-018362-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1829635/000110465926018362/tm266952d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-018362

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer